Glucagon‐like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta‐analysis of randomized placebo‐controlled outcome trials
Authors' conclusion
Treatment with GLP1-RA did not reduce HF hospitalizations and mortality in patients with concomitant T2D and HF, but may prevent new-onset HF and mortality in patients with T2D without HF. The reduction of atherosclerotic events with GLP1-RA was not influenced by HF history status.
Study context
- Population
- Stable ambulatory patients with T2D, with and without heart failure (HF) history; 8460 (16%) had HF history
- Participants
- 54,092 patients7 RCTs
- Comparison
- GLP-1 RA vs placebo, by HF history
- Outcome
- Composite of:
- HF hospitalization
- Cardiovascular death
Methodological detailsrandom-effects, placebo-controlled trials, HF subgroup analyses
- Random-effects
- Placebo-controlled trials
- HF subgroup analyses
Pooled result
As reported in the abstract
HF hospitalization or cardiovascular death, by HF history
GLP1-RA vs PlaceboHazard ratio (95% CI)
With HF history
0.96(0.84–1.08)
Without HF history
0.84(0.76–0.92)
Further pooled results
| Outcome | HR (95% CI) | |
|---|---|---|
| All-cause death, by HF historyGLP1-RAvs PlaceboWith HF history | 0.98 (0.86–1.11) | |
| All-cause death, by HF historyGLP1-RAvs PlaceboWithout HF history | 0.85 (0.79–0.92) | |
| Atherosclerotic events, by HF historyGLP1-RAvs PlaceboWith HF | 0.85 (0.75–0.97) | |
| Atherosclerotic events, by HF historyGLP1-RAvs PlaceboWithout HF | 0.88 (0.83–0.93) | |
| 0.512Hazard ratio (log scale) |
Original publication
Glucagon‐like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: A meta‐analysis of randomized placebo‐controlled outcome trials. Diabetes Obes Metab. Published 20 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →